Resistance to Ibrutinib

Publication
Article
Special ReportsHematologic Malignancies
Volume 1
Issue 1

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

View more about the treatment of chronic lymphocytic leukemia > >

Articles in this issue
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
In the Pipeline: Potential New Treatments for AML
In the Pipeline: Potential New Treatments for AML
Epidemiology in B-Cell Malignancies
Epidemiology in B-Cell Malignancies
Pathogenesis of Follicular Lymphoma
Pathogenesis of Follicular Lymphoma
Resistance to Ibrutinib
Resistance to Ibrutinib
IPI-145 and ABT-199 for Lymphoid Malignancies
IPI-145 and ABT-199 for Lymphoid Malignancies
BCL-2 Inhibitor Combo May Offer Remissions in CLL
BCL-2 Inhibitor Combo May Offer Remissions in CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
Recent Videos
Related Content
FDA Updates Fludarabine Labeling Under Project Renewal Initiative

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

Jordyn Sava
November 20th 2024
Article

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

Jordyn Sava
November 15th 2024
Article

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Exploring New Therapies and Sequencing in Relapsed CLL

Exploring New Therapies and Sequencing in Relapsed CLL

Ariana Pelosci
November 14th 2024
Article

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Read More

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More